Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of rheumatoid arthritis (according to the 1987 ACR classification criteria OR a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for rheumatoid arthritis ) for at least 6 months prior to screening~* Must have been treated with MTX 12.5-25 mg/week, for at least 6 weeks prior to screening. Doses of 10 to \< 12.5mg/week are allowed if there is documented intolerance~* Have moderately to severely active rheumatoid arthritis disease with at least 6 tender and 6 swollen joints~* CRP ≥1.2 times the upper limit of normal (central laboratory) or erythrocyte sedimentation rate of more than 28mm/hour~* Intolerant or inadequate response to treatment (ie, TNF blocker failure)≥1 licensed TNF-blocker therapies within 2 years of screening~Exclusion Criteria:~* Have a diagnosis of any other inflammatory arthritis or secondary, noninflammatory type of arthritis, such as psoriatic arthritis, lupus, gout, or ankylosing spondylitis~* Wheelchair bound or bedridden.~* Disease modifying antirheumatic drugs (DMARDs) other than MTX.~* Treatment with tocilizumab or any other anti-IL-6 investigational therapies at any time.~* Treatment with other biologics within 4-24 weeks (depending on the biologic)~* History of ongoing, chronic or recurrent infections or recent serious or life-threatening infection~* Known concurrent acute or chronic viral hepatitis B or C infection or human immunodeficiency virus (HIV) infection.~* Vaccinations (other than injectable influenza or pneumococcal) within 8 weeks prior to screening or plan to receive vaccines during the study~* Concurrent or history of malignancy with the exception of nonmelanoma skin cancer successfully treated more than 2 years prior to screening or cervical cancer successfully treated more than 5 years prior to screening.~* History of chronic alcohol abuse or drug addiction within the last 1 year or current drug addiction or use of illicit drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDP6038 60 mg sc every 2 weeks plus methotrexate (Type: EXPERIMENTAL): None
- CDP6038 60 mg sc every 4 weeks plus methotrexate (Type: EXPERIMENTAL): None
- CDP6038 120 mg sc every 2 weeks plus methotrexate (Type: EXPERIMENTAL): None
- CDP6038 120 mg sc every 4 weeks plus methotrexate (Type: EXPERIMENTAL): None
- CDP6038 240 mg sc every 2 weeks plus methotrexate (Type: EXPERIMENTAL): None
- CDP6038 240 mg sc every 4 weeks plus methotrexate (Type: EXPERIMENTAL): None
- Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate (Type: ACTIVE_COMPARATOR): None
- Placebo sc every 2 weeks plus methotrexate (Type: PLACEBO_COMPARATOR): None
- Placebo sc every 4 weeks plus methotrexate (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete